Galway medtech Ceroflo raises €5 million to develop device to treat and prevent stroke

Ceroflo has raised €5m via EIIS to advance its ICAD stroke-prevention stent, backed by Neuravi founders and veteran Irish medtech leaders.

BRAIN 2024: ICAD confronted as globally relevant yet under-addressed stroke aetiology

Global experts at BRAIN 2024 highlighted ICAD as a widespread, under-treated cause of stroke, underscoring urgent need for better devices like those developed by Ceroflo.

Innovative stroke solution takes step closer to patient trials

Ceroflo has launched a second EIIS funding round with DHKN to advance its SubMax stent toward first-in-human trials for ICAD stroke prevention.

Galway-based Ceroflo raises €6.4m to advance stroke treatment

Ceroflo has raised €6.4m to fund first-in-human trials of its SubMax stent for ICAD stroke prevention and global regulatory expansion.

Ceroflo CEO: How we’re tackling the current challenges facing EU medtech companies

Ceroflo’s Chloe Brown talks to SiliconRepublic.com about her role as CEO and the several challenges currently facing medtech companies in the EU.

Cereflo led consortium secures €3.6m from Disruptive Technologies Innovation Fund

Ceroflo secured €3.6m DTIF funding with Advant Medical and ATU to advance its SubMax stent toward human trials for ICAD stroke treatment.

Investing in the next frontier in the treatment and prevention of stroke

Irish medtech startup Ceroflo is raising up to €5m to develop a novel stent for stroke prevention, led by a proven Neuravi team.

CeroFlo Emerges from Stealth to Tackle Intracranial Atherosclerotic Disease